The FDA has approved Madrigal Pharmaceuticals’ resmetirom, sold under the brand name Rezdiffra, as the first therapy for MASH, also…
Browsing: Hot headlines in GI
Key Points: The New England Journal of Medicine has published the results of the pivotal BLUE-C study on Cologuard Plus™.…
Conducted by the Regenstrief Institute and Indiana University School of Medicine, the study involved over 21,000 average-risk patients across 186…
Key Points: The acquisition positions Mahana Therapeutics as a global leader in digital treatment solutions for chronic conditions, particularly in…
Key Points: Over half (55%) of gastroenterologists would take a salary cut for a better work-life balance. The primary way…
Annual costs of alcohol-associated liver disease are forecasted to rise from $31 billion in 2022 to $66 billion in 2040,…
The article underscores the growing concern about colorectal cancer rates and the importance of raising awareness. The White House has…
Change Healthcare, a UnitedHealth Group (UHG) technology company, suffered a ransomware attack, disrupting provider access to payer reimbursements. In response…
Key Points: Conducted in partnership with The Harris Poll, Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, released…
In the U.S., over 40% of children suffer from at least one chronic condition such as eczema, asthma, diabetes, obesity,…